Rucaparib for BRCA-Mutated Castration-Resistant Prostate Cancer: Nicholas Vogelzang, MD

In this interview, Nicholas Vogelzang, MD, speaks with i3 Health about the recent FDA approval of rucaparib (Rubraca®, Clovis Oncology, Inc.) for the treatment of patients with metastatic BRCA-mutated castration-resistant prostate cancer (CRPC) who previously received one line of taxane-based chemotherapy and at least one line of androgen receptor-directed therapy. Dr. Vogelzang, Clinical Professor of Medicine at the University of Nevada School of Medicine and one of the investigators of the TRI...
Continue reading

Olaparib Approved: HRR-Mutated Metastatic Castration-Resistant Prostate Cancer

The FDA has approved olaparib (LynparzaTM, AstraZeneca Pharmaceuticals LP) for adult patients with homologous recombination repair (HRR)–mutated metastatic castration-resistant prostate cancer (CRPC) who experience disease progression after treatment with enzalutamide or abiraterone acetate. In addition, the FDA approved two companion diagnostic devices: FoundationOne® CDx (Foundation Medicine, Inc.), for the identification of HRR gene alterations, and BRACAnalysis CDx®(Myriad Genetics, Inc...
Continue reading

The Current State of CRPC Management With Judd W. Moul, MD, FACS

In the past decade, much progress has been made in the management of castration-resistant prostate cancer (CRPC), with numerous new agents improving outcomes in patients with this disease. However, many challenges still remain. In this interview with i3 Health, Judd W. Moul, MD, FACS, Professor of Urologic Surgery at the Duke School of Medicine, discusses strategies that community oncologists and urologists can utilize to determine the best treatment for their patients. He also discusses the rol...
Continue reading

Castration-Resistant Prostate Cancer: Guiding Patients Through Treatment With Brenda Martone, MSN, ANP-BC, AOCNP

​Androgen deprivation therapy is a cornerstone of treatment for progressive prostate cancer, but over time, many patients stop responding to this treatment, developing a resistance to castration. Until recently, nonmetastatic castration-resistant prostate cancer (CRPC) lacked effective treatment options; this situation has changed dramatically with the rise of several new agents. Metastatic CRPC is the primary cause of prostate-related mortality, yet advances in treatment are extending survival....
Continue reading

Educational Need in Castration-Resistant Prostate Cancer

Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment, including patient health status, rate of disease progression and disease burden, presence of bone or visceral metastases, mechanism of action and tolerability of available agents, and prior lines of therapy and response. Baseline data collected from i3 Health's continuing me...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.